Drug Information Journal - March 2009 - (Page 175) Trends in Meta-analysis BIOSTATISTICS 175 2. JAMA. Users’ guides interactive. Available at: http://pubs.ama-assn.org/misc/usersguides.dtl. Accessed January 30, 2008. 3. Centre for Evidence-Based Medicine. Available at: http://www.cebm.net. Accessed January 30, 2008. 4. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Available at: http://www.cochrane.org/resources/handbook/. Accessed January 30, 2008. 5. Allen IE, Olkin I. Estimating time to conduct a meta-analysis from number of citations retrieved. JAMA. 1999;282:634–635. 6. Steinberg K, Smith S, Stroup D, et al. Comparison of effect estimates from a meta-analysis of summary data from published studies and from a meta-analysis using individual patient data for ovarian cancer studies. Am J Epidemiol. 1997;145: 917–925. 7. Stewart LA, Parmar MB. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet. 1993;341:418–422. 8. Berlin JA, Colditz GA. The role of meta-analysis in the regulatory process for foods, drugs, and devices. JAMA. 1999;281:830–834. 9. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of results of metaanalyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA. 1992;268:240–248. 10. Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol. 1995; 48:45–57. 1 Juni P, Nartey L, Reichenbach S, et al. Risk of car1. diovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364:2021–2029. 12. Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project: a combined analysis of three large-scale randomized trials: Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol. 1995;76:899–905. 1 Baigent C, Keech A, Kearney PM, et al. Efficacy 3. and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278. 14. Province MA, Hadley EC, Hornbrook MC, et al. The effects of exercise on falls in elderly patients. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. A preplanned meta-analysis of the FICSIT Trials. Frailty and Injuries: Cooperative Studies of Intervention Techniques. JAMA. 1995;273:1 341–1 347. Diener HC, the Executive Steering Committee on behalf of the SPORTIF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor Ximelagatran in patients with nonvalvular atrial fibrillation: pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis. 2006;21:279–293. Berger JO. Bayesian analysis: a look at today and thoughts of tomorrow. J Am Stat Assoc. 2000; 95:1269–1276. Berry D. Bayesian statistics. Med Decis Making. 2006;26:429–430. Raudenbush SW, Bryk AS. Empirical Bayes metaanalysis. J Edu Stat. 1985;10:78–98. Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. An introduction to Bayesian methods in health technology assessment. BMJ. 1999;319:508–512. Schmid CH. Using Bayesian inference to perform meta-analysis. Eval Health Prof. 2001;24:165–189. Tunis S, Sheinhait IA, Schmid C, Bishop DJ, Ross SD. The efficacy of lansoprazole compared to histamine-2 receptor antagonists in healing gastric ulcers: a meta-analysis. Clin Ther. 1997;19:743– 757. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683– 691. McAlister FA, Laupacis A, Wells GA, Sackett DL, for the Evidence-Based Medicine Working Group. Users’ guides to the medical literature: XIX. Applying clinical trial results; B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA. 1999;282: 1371–1 377. Caldwell DM, et al. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331:897–900. Ross S, Klawansky S, Allen IE. Indirect comparisons of drugs using meta-analysis: validation of results. Value in Health. 2001;4:55. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Eng J Med. 2001; 344:1888–1894. Eliot W, Mayer P. Incident diabetes in clinical tri- Drug Information Journal http://pubs.ama-assn.org/misc/usersguides.dtl http://www.cebm.net http://www.cochrane.org/resources/handbook/
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.